AI and Cancer Research (Top Journals) ── Pancreatic ── 2026-09-30

New papers on cancer and AI from 26 medical, oncology and general journals with an impact factor of 10 or more, collected from the journals' own websites and selected by Jev (an AI that makes language judgements): is it original research, is AI central, which of six themes, and does it concern treatment or trials. Summaries are written from each abstract only and make no claim about efficacy or safety.

Pancreatic cancer: treatment, trials and AI

• Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026-07-27 · Evidence: retrospective observational development cohort with external validation in a randomized phase III trial

  Whole-slide images from a retrospective multicentric series of 231 resected PDAC patients were used to build PANCprAId, estimating relative benefit from adjuvant GEM versus mFOLFIRINOX. In the randomized PRODIGE-24/CCTG PA6 trial (n=313), regimen-specific histology scores stratified outcomes (HR 1.69 and 2.02), and an interaction with cancer-specific survival was reported (P=.001).

• AI-driven tumor heterogeneity quantification and survival prediction in pancreatic ductal adenocarcinoma.
  NPJ digital medicine · 2026-07-20 · Evidence: observational multi-cohort prognostic model development and validation study

  HPSurv combines tissue classification, quantification of spatial tumor heterogeneity and a survival Transformer applied to whole-slide images for individualized overall survival prediction in PDAC. Developed and evaluated in 1020 patients across five independent cohorts, it reported a mean C-index of 0.761 and time-dependent AUCs of 0.936, 0.877 and 0.772 at 6 months, 2 and 3 years.

← Back to this issue